Uncategorized
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals submits an NDA to the U.S. FDA for KPI-121 0.25%, which, if approved, could be the first FDA-approved product for the temporary relief of signs and symptoms of dry eye disease.